Replies to post #50828 on US Stem Cell Inc (USRM)

[Havoc23]

The only logical reasoning for reactivion of the trial is because RMAT designation is coming imo

These trials are very expensive and without RMAT, the FDA knows it would be extremely difficult to continue the trials.

So the FDA wouldn't have them reactivate the trial if they weren't looking positively at RMAT designation possibilities.